证券代码：300519 证券简称：新光药业 公告编号：2025-006 浙江新光药业股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席王震召集，会议通知于 2025 年 4 月 7 日以电 子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2025 年 4 月 17 日在公司会议室召开，采取现场投票的 方式进行表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席王震先生主持，公司董事会秘书、财务总监 和证券事务代表列席了本次监事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等 法律法规和《公司章程》的有关规定。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《2024 年度监事会工作报告》 具体内容详见公司公布在中国证监会指定创业板信息披露网站的《2024 年 度监事会工作报告》。 表决结果：赞成 3 票， ...

证券代码：300519 证券简称：新光药业 公告编号：2025-005 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长王岳钧先生召集，会议通知于 2025 年 4 月 7 日以 电子邮件、专人送达、电话等形式送达全体董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 4 月 17 日在公司会议室召开，本次会议采用现 场会议方式召开并表决。 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长王岳钧先生主持，公司监事和高级管理人员列席 了本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等 法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 浙江新光药业股份有限公司 会议审议并通过了如下议案： 1、审议通过《2024 年度总经理工作报告》 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 2、审议通过《2024 年度董事会工作报告》 公司《2024 ...

证券代码：300519 证券简称：新光药业 公告编号：2025-007 浙江新光药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开 第五届董事会第三次会议、第五届监事会第三次会议，审议通过了《关于公司 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年度股东大会审议。 现将具体情况公告如下： 一、审议程序 1、董事会意见 公司第五届董事会第三次会议审议通过了《关于 2024 年度利润分配预案的 议案》。董事会认为，公司 2024 年利润分配预案是在综合考虑了公司的实际经 营情况和长远可持续发展后确定的对投资者的合理回报方案，同意该项议案并同 意将此议案提交公司 2024 年度股东大会审议。 2、2025 年第一次独立董事专门会议意见 公司 2025 年第一次独立董事专门会议审议认为：公司 2024 年度利润分配预 案与公司成长性相匹配，符合相关法律法规及公司章程的规定，符合公司《2022- 2024 年公司 ...

Financial Performance - The company's operating revenue for 2024 was ¥267,659,927.41, a decrease of 1.01% compared to ¥270,399,837.67 in 2023[16]. - The net profit attributable to shareholders for 2024 was ¥50,389,992.99, down 21.70% from ¥64,356,480.65 in 2023[16]. - The net profit after deducting non-recurring gains and losses was ¥45,393,968.53, reflecting a decline of 24.50% from ¥60,123,577.68 in the previous year[16]. - The basic earnings per share for 2024 was ¥0.31, a decrease of 22.50% compared to ¥0.40 in 2023[16]. - The total assets at the end of 2024 were ¥909,781,335.37, down 2.22% from ¥930,405,790.36 at the end of 2023[16]. - The net assets attributable to shareholders decreased by 1.61% to ¥830,531,829.60 at the end of 2024 from ¥844,120,768.19 at the end of 2023[16]. - The cash flow from operating activities for 2024 was ¥53,434,052.26, a slight increase of 0.27% from ¥53,290,425.47 in 2023[16]. - The weighted average return on equity for 2024 was 6.06%, down from 7.62% in 2023[16]. - The company reported a total of 4,996,024.46 in non-operating income for 2024, an increase of 18.1% compared to 4,232,902.97 in 2023[22]. - The company achieved total operating revenue of 26,765.99 million yuan, a decrease of 1.01% compared to the same period last year[38]. - The company's operating costs amounted to 17,699.02 million yuan, an increase of 11.46% year-on-year[38]. - The comprehensive gross profit margin for the company was 33.83%[38]. - The gross profit margin for the pharmaceutical manufacturing industry was 33.83%, a decrease of 7.44% from the previous year[43]. Market and Industry Trends - The company operates in the pharmaceutical manufacturing industry, which is experiencing strong demand due to an aging population and increased health awareness[25]. - By the end of 2024, the elderly population (60 years and above) in China is projected to reach 310 million, accounting for 22% of the total population[26]. - The pharmaceutical industry is expected to continue growing due to increasing healthcare investments and the promotion of TCM by the government[26]. - The company anticipates that the demand for TCM will rise as public trust in its efficacy in health management increases[26]. - The pharmaceutical industry in China is experiencing stable growth due to increasing healthcare investments, aging population, and deepening medical reforms, providing favorable conditions for the company's business development[34]. Product Development and Innovation - The company is focusing on integrating digital technologies into TCM practices to improve service quality and efficiency over the next 3-5 years[29]. - The company has developed a sugar-free version of Huangqi Shengmai Drink and a unique product, Huangqi Shengmai Granules, to cater to the needs of patients sensitive to sugar[35]. - The company is developing new products, including a new drug "YHTKL," aimed at enriching the product line and enhancing core competitiveness[54]. - The company is conducting clinical research to improve the efficacy and safety of existing products, which is anticipated to enhance market competitiveness[54]. - The company has established partnerships with several research institutions to enhance product development and innovation[40]. Marketing and Sales Strategy - The marketing strategy primarily involves a distributor model, where products are sold to distributors who then supply hospitals, pharmacies, and clinics[33]. - The company plans to enhance its marketing network, focusing on both domestic and expanding into provincial markets, while solidifying its leading products[83]. - The company will strengthen production management to ensure product quality and comply with new GMP standards, aiming to improve labor productivity and product quality[84]. Research and Development - The company invested a total of 1,262.42 million yuan in R&D, accounting for 4.72% of total operating revenue[40]. - The company has 11 core independent intellectual property rights, including 6 invention patents obtained through independent research and development[38]. - Research and development expenses decreased by 16.59% to ¥12,624,156.44 in 2024 from ¥15,134,245.96 in 2023[51]. - The number of R&D personnel decreased by 14% from 50 in 2023 to 43 in 2024, with the proportion of R&D staff dropping from 15.87% to 13.61%[53]. Governance and Compliance - The board of directors consists of 9 members, including 3 independent directors, and held 5 meetings during the reporting period, reviewing 34 proposals[92]. - The supervisory board, comprising 3 members, held 5 meetings and reviewed 19 proposals, ensuring effective supervision of the company's financial and managerial compliance[92]. - The company emphasizes investor relations management, utilizing multiple channels for communication and actively responding to investor inquiries[94]. - The company has established performance evaluation standards and incentive mechanisms for directors and senior management, ensuring transparency in appointments[95]. - The company is committed to maintaining compliance with regulatory requirements regarding independent directors[102]. Risk Management - The company recognizes risks related to policy changes in the pharmaceutical industry, which may impact production and sales[86]. - The company faces concentration risk with its main products, as three leading products significantly influence revenue and profitability[86]. - The company is addressing market expansion risks, as over 70% of sales revenue comes from the Zhejiang region, making it vulnerable to local market changes[87]. - The company will implement measures to manage raw material price volatility, which could adversely affect profitability[87]. - The company emphasizes the importance of internal management and cost reduction strategies to cope with rising material and labor costs[84]. Corporate Social Responsibility - The company donated 1 million yuan to the Shengzhou Charity Association for educational and healthcare initiatives, and 8,000 yuan to the local community mutual aid fund[146]. - The company has implemented strict wastewater discharge standards, with actual emissions of COD at 1.193 tons, well within the permitted limit of 8.48 tons[142]. - The company has achieved ISO 14001 environmental management system certification, ensuring compliance with environmental regulations and effective monitoring of emissions[143]. Shareholder Information - The company achieved a shareholder participation rate of 56.26% in the 2023 annual general meeting held on May 17, 2024[99]. - The total number of shareholders at the end of the reporting period was 15,470, with a slight increase from 15,369 at the beginning of the period[191]. - The company’s total share capital remains at 160,000,000 shares, with 28.69% being restricted shares and 71.31% being unrestricted shares[188]. - The company has not experienced any changes in its controlling shareholder during the reporting period[193]. Future Outlook - The company aims for a revenue growth target of 0-10% for 2025, emphasizing that this is not a commitment to investors[85]. - The company plans to continue its market expansion strategy, focusing on enhancing user engagement and product offerings[174]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and operational capabilities[174].

证券代码：300519 证券简称：新光药业 公告编号：2025-002 浙江新光药业股份有限公司 关于公司持股 5%以上股东股份减持计划期限届满的公告 持股 5%以上的股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2024 年 11 月 29 日披露了 《关于持股 5%以上股东减持股份预披露公告》（公告编号：2024-042），公司持股 5%以上股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）计划于公告披 露之日起 15 个交易日后的 3 个月内通过集中竞价交易方式和大宗交易方式共计减 持其持有的公司股份不超过 3,200,000 股（即不超过公司总股本的 2%）。 近日，公司收到股东和丰投资提交的《关于股份减持计划期限届满的告知函》， 本次减持股份计划期限届满。在本次减持计划期间，和丰投资通过深圳证券交易所 以大宗交易方式共减持公司股份 1,446,000 股（占公司总股本比例 0.9038 ...

证券代码：300519 证券简称：新光药业 公告编号：2025-001 浙江新光药业股份有限公司 持股 5%以上的股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 关于持股 5%以上股东减持股份比例达到 1%的公告 2025 年 1 月 7 日，浙江新光药业股份有限公司（以下简称"新光药业"、"公 司"）收到公司股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）的《关 于股份减持进展的告知函》，和丰投资自 2023 年 3 月 29 日至 2025 年 1 月 6 日期 间通过集中竞价方式减持新光药业股份 1,004,100 股、通过大宗交易方式减持新 光药业股份 1,446,000 股，合计减持新光药业股份 2,450,100 股，占新光药业总 股本的比例 1.5313%。自公司 2023 年 3 月 21 日披露《关于持股 5%以上股东减持 股份比例达到 1%的公告》（公告编号：2023-005）以来，和丰投资持股比例变动 再次达到 1%。根 ...

证券代码：300519 证券简称：新光药业 公告编号：2024-042 浙江新光药业股份有限公司 关于持股 5%以上股东减持股份预披露公告 公司持股 5%以上股东嵊州市和丰投资股份有限公司保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有浙江新光药业股份有限公司（简称"本公司"或"公司"）股份 28,226,900 股（占公司总股本比例 17.64%）的嵊州市和丰投资股份有限公司（简称"和丰投资"） 计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价交易方式和大宗交 易方式共计减持其持有的不超过 3,200,000 股公司股份（即不超过公司总股本的 2%）。其中：计划于本公告披露之日起 15 个交易日后的 3 个月内以集中竞价交易 方式减持其持有的不超过 1,600,000 股公司股份（即不超过公司总股本的 1%）；计 划于本公告披露之日起 15 个交易日后的 3 个月内以大宗交易方式减持其持有的不 超过 1,600,000 股公司股份（即不超过公司总股本的 1%）。 近日，公司 ...

Financial Performance - The company's revenue for Q3 2024 was ¥70,001,422.20, representing a 4.36% increase year-over-year[3] - Net profit attributable to shareholders decreased by 39.11% to ¥12,274,690.46 in Q3 2024[3] - The net profit after deducting non-recurring gains and losses was ¥11,979,179.22, down 38.86% compared to the same period last year[3] - Net profit for Q3 2024 was CNY 37,782,359.75, down from CNY 58,699,769.38 in the same period last year, reflecting a decrease of 35.6%[17] - The total comprehensive income for the period attributable to the parent company was CNY 37,798,974.14, a decrease from CNY 59,129,468.24 in the previous period[18] - Basic and diluted earnings per share for the period were both CNY 0.24, down from CNY 0.37 in the previous period[18] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥892,451,704.76, a decrease of 4.08% from the end of the previous year[3] - Total assets decreased to CNY 892,451,704.76 from CNY 930,405,790.36, a reduction of 4.1%[16] - Total liabilities decreased to CNY 74,531,962.43 from CNY 86,285,022.17, a decline of 13.5%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥35,382,757.18, down 15.25% year-over-year[3] - Cash received from operating activities decreased by 60.24% to ¥5,841,377.75 compared to ¥14,690,256.67 in the same period last year, primarily due to reduced bank deposit interest[8] - Cash flow from operating activities generated a net amount of CNY 35,382,757.18, compared to CNY 41,748,650.66 in the previous period[20] - Cash inflow from operating activities totaled CNY 212,613,452.57, down from CNY 232,562,979.50 in the previous period[20] - Cash outflow from operating activities was CNY 177,230,695.39, compared to CNY 190,814,328.84 in the previous period[20] - The net cash flow from investing activities turned negative at -¥90,716,421.32 compared to a positive ¥20,486,792.61 in the same period last year, primarily due to increased purchases of financial products[8] - The net cash flow from investing activities was -CNY 90,716,421.32, a significant decrease from CNY 20,486,792.61 in the previous period[20] - The ending balance of cash and cash equivalents was CNY 424,612,128.76, down from CNY 604,265,223.53 at the end of the previous period[21] Investments and Financial Assets - The company reported a significant increase in trading financial assets, rising by 58.06% to ¥245,000,000.00 due to increased investment in financial products[6] - The company’s trading financial assets increased to ¥245,000,000.00 from ¥155,000,000.00 at the beginning of the period[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,112[9] - Major shareholder Wang Yuejun holds 38.25% of the shares, amounting to 61,200,000 shares[9] Operating Costs and Expenses - Total operating costs increased to CNY 177,847,718.97 from CNY 151,115,999.35, marking a rise of 17.8% year-over-year[16] - Research and development expenses were CNY 9,618,279.84, down from CNY 11,763,165.15, a decrease of 18.3%[17] Accounts Receivable and Payable - Accounts receivable increased by 70.28% to ¥17,009,136.33, attributed to higher shipments compared to the previous year[6] - Accounts receivable decreased to CNY 17,009,136.33 from CNY 9,988,937.91, indicating a significant increase of 70.3%[15] - The company experienced a 66.53% increase in payable taxes, totaling ¥7,935,946.99, primarily due to increased VAT payable[7] - The company reported a significant increase in accounts payable, which decreased to CNY 55,286,366.71 from CNY 63,875,802.19, a reduction of 13.5%[16] Taxation - Taxes paid decreased by 55.75% to ¥17,312,431.02 from ¥39,123,928.86 year-on-year, mainly due to tax payments from previous years made in the same period last year[8]

4、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 证券代码：300519 证券简称：新光药业 公告编号：2024-036 浙江新光药业股份有限公司 第五届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 1、浙江新光药业股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日 召开 2024 年度第一次临时股东大会选举产生了第五届监事会非职工代表监事， 与公司职工代表大会选举产生的职工代表监事共同组成了第五届监事会。公司第 五届监事会第一次会议经全体监事一致同意豁免会议通知期限要求，现场发出会 议通知，并于 2024 年 8 月 23 日上午 9：30 在浙江省嵊州市剡湖街道环城西路 25 号公司会议室以现场方式召开。 2、本次会议应出席监事 3 名，实际出席监事 3 名。公司董事会秘书、财务 总监列席了会议。 3、本次会议由监事会半数以上监事共同推举王震先生主持。 二、 监事会会议审议情况 1、审议通过了《关于选举公司第五届监事会主席的议案》 经审议，监事会同意选举 ...

浙江新光药业股份有限公司 2024 年半年度报告全文 浙江新光药业股份有限公司 2024 年半年度报告 公告编号：2024-034 2024 年 8 月 1 浙江新光药业股份有限公司 2024 年半年度报告全文 请广大投资者注意投资风险。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王岳钧、主管会计工作负责人邢宾宾及会计机构负责人(会计 主管人员)邢宾宾声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 | --- | |--------------------------------------------------------------------| | | | 公司在生产经营过程中，可能存在行业政策变动、医保政策变动、产品 | | 结构集中、市场拓展、原材料价格波动等风险因素。本报告期涉及的未来计 | | 划等前瞻性陈述，不构成公司对投资者的实质承诺，投资者及相关人士均应 | | 对此保持足够的风险认 ...